drugset
drugset / Trial / NCT02170831

Multiple Oral Doses of BIBR 1048 MS Solution in Healthy Volunteers

NCT02170831 ↗

Phase 1 Completed 40 enrolled Boehringer Ingelheim
RandomizedParallel-groupOpen-labelTreatment

Summary

To assess safety, pharmacokinetics and the effect of BIBR 1048 MS on coagulation parameters.

Timeline

Start
1999-05
Primary completion
1999-07
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Dabigatran etexilate Unknown 50 mg Oral
Subject Dabigatran etexilate Unknown 100 mg Oral
Subject Dabigatran etexilate Unknown 200 mg Oral
Subject Dabigatran etexilate Unknown 400 mg Oral

Indications

No indication recorded.